friday januari market open report fourth quarter
full year financi result exhibit miss top-lin
bottom-lin expect guid non-gaap ep
growth year-over-year midpoint revenu quarter billion
estim billion consensu billion world-wide humira revenu
billion estim billion consensu billion imbruvica
revenu record billion line consensu estim
billion hcv franchis sale million estim million
consensu million non-gaap ep estim
consensu full-year non-gaap ep estim
consensu complet varianc analysi expect
consensu actual result summar exhibit manag guidanc
project top-lin growth ep growth declin billion
intern humira sale expect due entri biosimilar europ
late higher previous project unit state guid humira
growth larg achiev price increas administ
begin year loss intern humira revenu expect made
humira growth unit state well growth hematolog oncolog
franchis lower humira sale estim billion
billion previous new non-gaap ep estim
previous within guidanc
return equiti ttm
biopharmaceut compani major busi franchis autoimmun oncolog virolog
area base north chicago illinoi
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
expect neg sentiment continu regard humira price pressur unit state sale eros
europ well billion write-off rova-t januari lower fair valu estim
share updat pipelin project shown exhibit maintain outperform
rate base valuat near-term growth driven imbruvica venclexta orilissa new launch
upadacitinib risankizumab robust dividend yield potenti acquisit boost medium-term
growth opinion model remov rova-t lower estim cystic fibrosi franchis
project top- bottom-lin compound-annual-growth-rate humira biosimilar entri note
previous project compound-annual-growth-rate beyond project top-
bottom-lin compound-annual-growth-rate respect previous note project
includ current market product late-stag pipelin candid given robust cash posit potenti lack
organ revenu growth beyond believ manag might contempl acquisit fuel medium- long-term
growth although continu trade signific discount peer group exhibit ascrib
median multipl percentil compar biotech pharmaceut group valuat
percentil previous due rova-t setback lack medium-term growth beyond thu
lower averag price-to-earnings multipl comp group time non-gaap ep estim time
estim time estim compar previou averag time time time
estim respect use formula arriv fair valu estim
fourth-quart net revenu billion repres growth year-ago period increas
sequenti top three product humira sale grew year-over-year imbruvica grew year-over-
year hcv franchis sale flat quarter-over-quart humira sale fail reach double-digit year-over-year
growth fourth quarter second quarter row exhibit world-wide year-over-year humira
growth result increas unit state decreas intern exhibit account
adjust sale quarter imbruvica revenu grew quarter-over-quart includ
increas sale increas intern profit share expect imbruvica continu domin
second-lin chronic lymphocyt leukemia cll set continu grow margin zone lymphoma mzl chronic
graft-versus-host diseas gvhd continu expand frontlin cll lucr set hcv franchis sale
fourth quarter total million flat third quarter note mavyret alreadi reach
global hcv market share highest script volum among singular hcv drug unit state
continu forecast peak market share mavyret franchis reach equilibrium gilead
updat estim follow manag note sinc launch humira biosimilar mid-octob
biosimilar reach intern market price discount rang depend
geographi lower full year revenu estim billion billion due decreas
humira intern sale estim billion billion previous decreas
humira sale estim billion billion previous
also updat estim hcv franchis imbruvica increas sale estim hcv
franchis billion billion due less price eros anticip also lower
imbruvica sale estim billion billion within manag guidanc new non-gaap ep
estim previous match guidanc year-over-year non-gaap ep growth
follow recent clinic setback record impair charg rova-t accordingli
remov valuat rova-t rovalpituzumab tesirin first product candid multibillion-dollar
acquisit stemcentrx larg extent repres solid tumor oncolog franchis previous
guid peak sale rova-t billion march post top-lin result rova-t third-lin small cell lung
cancer sclc came expect matter worsen decemb halt phase trial
rova-t second-lin sclc therapi phase meru trial rova-t first-lin treatment sclc remain
activ releas statement record impair charg intang asset acquisit
stemcentrx estim net impact billion billion intang asset remain monitor due
numer clinic setback record impair charg remov rova-t valuat
reduc peak market share galapagoss glpg cf collabor
due delay timelin disappoint efficaci octob assum full develop
commerci respons cf program partner galapago program initi delay due
decis proceed plan second tripl combin studi result extend negoti
period top-lin result part falcon studi show dual potenti corrector combo
produc maximum mean absolut improv percent predict forc expiratori volum one second
percentag point homozyg patient compar observ vertex doubl combo
symdeko market perform howev ad second corrector anoth day result
increas competit data vertex show symdeko tripl combo produc
maximum mean absolut improv percentag point homozyg patient significantli
better galapagoss tripl combo proteostasi pti anoth competitor cf market potenti
corrector doubl combo led maximum mean absolut improv percentag point
seemingli better vertex symdeko tripl combo anticip proteostasiss tripl combo data
amplifi come week due disappoint efficaci result date increasingli delay
timelin reduc estim peak market share galapagoss cf franchis
result peak sale estim million billion previous
look number near-term product launch multibillion-dollar potenti well label expans
within key franchis throughout next month drive top- bottom-lin growth continu
support growth neg eu biosimilar impact humira headlin note imbruvica sale
expect fuel frontlin cll studi support continu penetr entrench
lucr set venclexta sale acceler label expans well orilissa approv juli
treatment endometriosis-associ pain unit state supplementari new drug applic snda heavi
menstrual bleed associ uterin fibroid track upadacitinib risankizumab pois
launch note two agent demonstr superior humira humira-approv
indic gradual replac humira coincid biosimilar entri sustain growth overal
immunolog franchis note medicin multibillion-dollar peak potenti manag expect
launch new product label expans earli believ help diversifi product mix
sustain growth follow loss exclus compani flagship product
expect upadacitinib approv launch rheumatoid arthriti forecast peak sale across numer
indic billion billion attribut sale ra risankizumab continu schedul like
approv launch first half moder sever psoriasi follow approv indic next
five seven year estim sale risankizumab reach billion orilissa launch august
treatment endometriosis-associ pain snda treatment heavi menstrual bleed hmb associ
uterin fibroid uf expect follow potenti approv project orilissa reach blockbust
statu bring sale billion across indic imbruvica continu cornerston
hematolog oncolog franchis eight approv indic sever late-stag develop continu
penetr frontlin cll largest market continu fuel growth maintain peak global sale estim
billion numer label expans venclexta expect beyond model billion
maintain outperform rate lower fair valu estim previous
assum price-to-earnings multipl median among pharma biotech peer due remov rova-t lower
estim cf franchis model project top- bottom-lin compound-annual-growth-rate respect
respect previous model
humira biosimilar enter unit state project top- bottom-lin compound-annual-growth-rate respect
respect previous note project includ current market product late-
stage pipelin candid although continu trade signific discount peer large-cap biotech
pharma compani also acknowledg neg sentiment surround humira pipelin setback need
acquisit boost medium-term growth result lower price-to-earnings multipl use valuat time
non-gaap ep estim time estim time estim compar previou
averag time time time estim respect use formula arriv
fair valu estim share
risk outperform rate includ earlier project biosimilar entri humira failur
market product fulfil expect failur key pipelin program commerci success polit
risk busi develop risk
humira hcv imbruvica total sg acquir in-process research expense- total oper interest expens net foreign exchang incom expens pre-tax incom tax net non- net intang asset separ costs- mileston acquir acquisit relat intang asset tax reform repatri impact relat tax law tax audit legal restructuring- chang fair valu conting transact charit contributions- collaboration- non- dividend per common weight averag share outstand compani report william blair inc incom william blair
actualwb estimatespreadvarianceq/q growthy/i growthcon estimate humira oper net compani report william blair estimatescurr quarterexhibit inc current quarter varianc analysi dollar billion except record record record record exclud top record abbviesourc william blair co estimatesexhibit inc estim product revenu william blair
consult last page report disclosur price factset william blair co epsexhibit inc earn comparablesconsensu compani reportsexhibit inc humira world-wide y/i y/i growth william blair
compani report william blair estimatesexhibit inc humira y/i growth y/i growtheu y/i growthww y/i growth import disclosur
